Application of linked DNA markers to screening families with multiple endocrine neoplasia type 2A.
There now exists a set of tightly linked markers to the gene causing multiple endocrine neoplasia type 2A. In this report we discuss the use of these markers for early and accurate prediction of gene carrier status in three different families. Factors that influence the probability of obtaining useful information with DNA markers are available family size, in particular the number of available affected individuals, and the extent of clinical and biochemical screening in the family. At present, DNA analysis has about a 3% risk of misdiagnosis; this risk is even lower if it is used in conjunction with the pentagastrin stimulation test for C-cell hyperplasia. With the combined tests, an individual at age 20 years may be scored as carrier or not with an estimated accuracy of 99%.
Telenius
H
H
Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, UK.
Mathew
C G
CG
Nakamura
Y
Y
Easton
D F
DF
Clark
J
J
Neumann
H P
HP
Ziegler
W H
WH
Schinzel
A
A
Ponder
B A
BA
D000293:Adolescent; D000328:Adult; D000368:Aged; D000483:Alleles; D004273:DNA, Neoplasm / Q000032:analysis*; D005260:Female; D006580:Genetic Carrier Screening / Q000379:methods; D008040:Genetic Linkage; D005819:Genetic Markers / Q000032:analysis*; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D008297:Male; D009377:Multiple Endocrine Neoplasia / Q000175:diagnosis / Q000235:genetics*; D011237:Predictive Value of Tests
D004273:DNA, Neoplasm; D005819:Genetic Markers